- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01992666
GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus (GENIAL)
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease for which the aetiology includes genet-ic and environmental factors. It is rare in children as compared to adults. The severity may be related to greater involvement of genetic factors in children. The impact of genetics in the development of SLE is important, and the risk of recurrence in siblings evaluated by lambda S ratio is 30 in SLE, while it is 15 for type-1 diabetes and 8 rheumatoid arthritis, thereby indicating high impact of genetics in SLE.
Recently, the group of Professor Yanick Crow in Manchester and other teams has identified new forms of lupus Mendelian genetics. The TREX1 and genes involved in the SAMHD1 frostbite lupus.
Nearly 2 % of all adult subjects with SLE have a heterozygous mutation in the TREX1 gene, which therefore represents the first genetic cause of SLE. The team of Professor Crow also identified the ACP5 gene that is responsible for SLE associated with Spondylo-epiphyseal enchondro-epiphyseal dysplasia (syndromic lupus). Other groups have identified mutations in two genes encoding a DNAse (DNAse1 and DNAse1L3) responsible for familial monogenic forms of SLE. These new genes SLE were identified through research of germ-line mutations in cases of lupus syndromic or family. In collaboration with Professor Crow, we are currently undergoing characterization of a novel gene of SLE in a family and we have identified a second locus identified in another family. The identification of these genes provides a better understanding of the mechanisms regulating immune tolerance in humans. The frequency of these genetic forms is not known. There is very little data on the immunological phenotype of these patients.
This is a clinical study to investigate the genetic and immunological abnormalities associated with pediatric SLE. The aim are to:
- study the genetics of pediatric SLE (or syndromic or family) and to search for mutations in the known genetic lupus or new genes in collaboration with Professor Yanick Crow.
- study the lymphocyte subpopulations and serum cytokines in pediatric patients with SLE (or syndromic or family) in the large Rhône- Alpes- Auvergne area.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France
- Service d'hématologie / oncologie pédiatrique - CHU
-
Besançon, France
- Néphrologie Pédiatrique - CHU Besançon
-
Bron, France
- Hôpital Femme Mère Enfant
-
Clermont Ferrand, France
- Service de Néphrologie Pédiatrique
-
Fort De France, France
- Service de pédiatrie - CHU Fort de France
-
Grenoble, France
- Service de Néphrologie et Rhumatologie Pédiatrique
-
Le Kremlin Bicêtre, France
- Service de Rhumatologie Pédiatrique - Hôpital de Bicêtre
-
Lille, France
- Service de médecine interne - Centre de référence des maladies rares
-
Lille, France
- Service de néphrologie, endocrinologie, maladie métabolique et hématologie bénigne pédiatriques - Hôpital Jeanne de Flandre
-
Lille, France
- édiatrie générale, urgences et maladies infectieuses, Hôpital Salengro
-
Lyon, France
- Service de Néphrologie - Hôpital Edouard Herriot
-
Marseille, France
- Centre de néphrologie et de transplantation rénale - Hôpital de la conception
-
Marseille, France
- Service de médecine infantile- Hôpital Nord
-
Metz, France
- Service de médecine interne - Hôpitaux privés de Metz
-
Montpellier, France
- ervice d'urgence et post-urgences pédiatriques - CHU Arnaud de Villeneuve
-
Nancy, France
- Service médecine infantile 2
-
Nantes, France
- Service de néphrologie pédiatrique - CHU de Nantes
-
Paris, France
- Service d'immunologie et rhumatologie pédiatrique - Centre de référence de maladies rhumatologiques et inflammatoires rares en pédiatrie-Hôpital Necker-Enfants malades
-
Paris, France
- Service de médecine interne - Hôpital Saint Antoine
-
Paris, France
- Service de pédiatrie générale - Hôpital Robert-Debré
-
Pierre-Bénite, France, 69495
- Médecine Interne Adulte - Centre Hospitalier Lyon Sud
-
Pierre-Bénite, France
- Service de Rhumatologie - Centre Hospitalier Lyon Sud
-
Rennes, France
- Service pédiatrie grands enfants-adolescents - CHU Hôpital Sud
-
Saint Etienne, France
- Hopital Nord
-
Saint Pierre, France
- Service de Pédiatrie Générale - CHU Réunion
-
Toulouse, France
- Service de néphrologie - médecine interne - Hypertension pédiatrique - Hôpital des enfants
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or female subject, major or minor of any age with SLE (defined according to the ACR criteria)
- Onset pediatric (<18 years) OR
- Syndromic Lupus (associated with growth retardation, neurological deficit not related to lupus, frostbite, lymphoproliferation, the kidney malformations, heart, lung, brain calcifications) OR
- Lupus in context with familial consanguinity OR
- Familial cases (2 cases of SLE related first degree relative) OR related topic of the first degree to a lupus patient participant (if family lupus or related parents) OR
- mother/father's lupus patient (in cas of simplex lupus)
- A person or beneficiary entitled to a social security scheme or similar
- Informed consent signed by the person (or parent / holding parental authority for minors)
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Blood sampling
|
Immunologic and genetic analysis from a single blood sample.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New genes identification
Time Frame: Once. At inclusion.
|
Description: Identification of genetic mutations in the following genes: TREX1, SAMHD1, ACP5, DNAse1, DNAse1L3, or in new lupus genes.
|
Once. At inclusion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological genotype and clinical abnormalities correlation
Time Frame: Once. At inclusion
|
Correlate genotype to immunological (interferon alpha, …) and clinical abnormalities (microcrania, growth retardation, …)
|
Once. At inclusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological component
Time Frame: Once. At inclusion
|
Identification of specific immunological factors of pediatric patients with SLE (or syndromic or family)
|
Once. At inclusion
|
Characterization of sub-groups: size, articular manifestations (SLEDAI), hematology (hemoglobin, platelets, G White, ANA, ds-DNA, C3, C4, CH50, creatinine, proteinuria.
Time Frame: Once. At inclusion
|
Once. At inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alexandre Belot, Dr, Hospices Civils de Lyon
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012.769
- 2012-A01449-34 (OTHER: ID-RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus (SLE)
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus | Juvenile SLEBrazil
-
AstraZenecaNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingSystemic Lupus Erythematosus (SLE)China
-
Cartesian TherapeuticsRecruitingSystemic Lupus Erythematosus (SLE)United States
-
Oklahoma Medical Research FoundationYale University; Columbia University; NYU Langone Health; Piedmont Heart Institute...RecruitingSystemic Lupus Erythematosus (SLE)United States
-
Phramongkutklao College of Medicine and HospitalCompletedSystemic Lupus Erythematosus, SLEThailand
Clinical Trials on Blood sampling
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance